Three radiation protocols currently used in treatment of leukemia patients before bone marrow transplantation (BMT) were investigated in a murine model (C57BLl 6 -C3H/HeJ) for BM allograft rejection. These include (a) a single dose of total body irradiation (8.5 Gy TBI delivered at a dose rate of 0.2 Gy/min), (b) fractionated TBI (12 Gy administered in six fractions, 2 Gy twice a day in 3 days, delivered at a dose rate of 0.1 Gy/min, and (c) hyperfractionated TBI (14.4 Gy administered in 12 fractions, 1.2 Gy three times a day in 3 days. delivered at a dose rate of 0.1 Gy/min). Donor-type chimerism 6 to 8 weeks after BMT and hematologic reconstitution on day 12 after BMT found in these groups were compared with results obtained in mice conditioned with 8 Gy TBI delivered at a dose rate of 0.67 Gy/min, routinely used in this murine model. The results in both parameters showed a marked advantage for the single dose 8.5 Gy TBI over all the other treatments. This advantage was found to be equivalent to a three-to fourfold increment in the BM inoculum when compared OTAL BODY irradiation (TBI) is a major component T of most conditioning protocols currently used before bone marrow transplantation (BMT) in treatment of leukemia and other malignancies. Several protocols using fractionated or hyperfractionated radiation together with administration of cyclophosphamide, either before or after TBI,' have previously resulted in adequate engraftment of donor BM cells and in satisfactory eradication of pathologic cells in some leukemias. Such an approach involves use of unseparated BM, however, and its success is hampered by a high incidence of acute and chronic graft-v-host disease (GVHD).* The recent use of T-cell-depleted BM has reduced the incidence of GVHD, but survival rates have not improved, owing to an increased rate of graft rejection and leukemia Animal studies," later confirmed by clinical data? strongly suggest that the prevention of GVHD is associated with reduced immune suppression of residual host lymphocytes and, consequently, with an increased expression of host-type with hyperfractionated radiation, which afforded the least favorable conditions for development of donor-type chimerism. The fractionated radiation protocol was equivalent in its efficacy to results obtained in mice irradiated by single-dose 8 Gy TBI, both of which afforded a smaller but not significant advantage over the hyperfractionated protocol. This model was also used to test the effect of radiation dose rate on the development of donor-type chimerism. A significant enhancement was found after an increase in dose rate from 0.1 to 0.7 Gy/min. Further enhancement could be achieved when the dose rate was increased to 1.3 Gy/min, but survival at this high dose rate was reduced. These results demonstrated indirectly that dose rate affects the expression of host-type pluripotent stem cells, the progeny of which appear 3 to 6 weeks after treatment with 8 Gy TBI delivered at a dose rate of 0.1 Gy/min, but which are eradicated if radiation is delivered at a dose rate of 1.3 Gy/min. 0 1990 by The American Society of Hematology.
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bone marrow cells. The presence of such host cells could contribute to graft failure, either by immune-mediated mechanisms or by stem cell competition. These observations, together with the demonstration that prevention of GVHD is associated with a higher relapse rate in several types of leukemia: indicate that, to benefit from GVHD prophylaxis, the conditioning protocol may have to be intensified.
Several studies have demonstrated that engraftment of T-cell-depleted BM can be enhanced by intensification of TBI.'.'' Toxicity levels a t different radiation dosages cannot easily be extrapolated from one species to another, however. Therefore, it is difficult to predict whether the exact radiation protocol that is both efficient and safe for use in animals will also be as safe for use in humans. It is also difficult to compare radiation protocols used in different BMT centers according to their clinical outcome, because other variations in transplantation procedure also affect the results. We attempted to overcome this difficulty by using a single mouse model in which different radiation protocols currently used in humans may be compared for their efficacy in promotion of T-cell-depleted BM allografts.
In this experimental model (C57BL/6 -C3H/HeJ mice), the relationship between BM cell dose and conditioning with TBI was documented in detail."-'3 Transplantation of more than 2 x lo6 donor-type BM cells into recipients conditioned with 9 Gy TBI led to donor-type chimerism in more than 95% of the mice, and graft rejection was detected only on transplantation of 5 2 x lo6 BM cells. Graft rejection was more frequent in mice conditioned with 8 Gy TBI. Transplantation of 3 x lo6 cells in animals irradiated with 8 Gy TBI resulted in only 5% to 30% donor-type chimeras, whereas in recipients of smaller BM doses, the reconstituted hematopoietic cells were of host type in more than 95% of the animals when measured 1 month after transplant." Chimerism reversals occurred largely during the first 3 to 4 weeks posttransplant12 and were very rare when chimerism status
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was tested from 6 weeks posttransplant on (T. Lapidot, unpublished observations, 1989) .
Several approaches effectively enhanced donor-type chimerism in this model. They included (a) booster irradiation to the spleen 3 to 4 days after TBI"; (b) administration of myeloablative drugs such as dimethyl myleran (DMM),I3 busulfan,14 or thiotepa14 in addition to TBI; and (c) an increase in BM cell dose."-13 The latter approach enabled us to demonstrate that the expression of host-type stem cells and their progeny depends not only on the aggressiveness of the conditioning protocol, but is also a function of BM engraftment rate. Slow donor-type grafts, associated with small BM inocula, will eventually revert to host-type cells, whereas rapid engraftment such as that observed after transplantation of 210 x lo6 T-cell-depleted BM cells will not allow recovery of host-type cells, even though the precursors of such cells are not completely destroyed by the conditioning protocol.
In the present study, we used this murine model to compare the efficacy of three major radiation protocols currently used to condition leukemia patients before BMT. These include (a) 8.5 Gy single-dose TB115,'6; (b) fractionated radiation of 12 Gy TBI, twice a day in 3 daysI7; and (c) hyperfractionated radiation (originally described by Shank et all8 and later modified by Brochstein et all9) of 14.4 Gy TBI, administered in 12 fractions (1.2 Gy each) three times daily for 4 days. In particular, we wished to include in this study the most intensive single-dose TBI protocol currently being used in human^.'^,'^
MATERIALS AND METHODS
Animals used were 8-to 12-week-old female C3H/HeJ and C57BL/6 mice obtained from the Roscoe B. Jackson Memorial Laboratory, Bar Harbor, ME. All mice were kept in small cages (five animals in each cage) and fed sterile food and acid water.
Mice were exposed to different radiation protocols, as described in the Results section, from a Gammabeam 150-A 6oCo source (produced by the Atomic Energy of Canada, Kanata, Ontario), at a focal skin distance of 25 cm.
BM cells were prepared according to Reisner et alZ0 with minor modifications?
Mice were bled from the retroorbital vein using heparin-coated glass capillaries. Blood samples were counted for hemoglobin, platelets, and WBCs in a Coulter Counter S+11 (Coulter Electronics, Luton, England).
Chimerism analysis was made by cytofluorimetry using anti-H2Kb and anti-H2Kk monoclonal antibodies (MoAbs), as described by Lapidot et al." The cells were pressed through stainless steel sieves to make cell suspensions in PJNaCI, and divided equally into three test tubes. The cells were then stained by indirect immunofluorescence; the first MoAb used was either anti-H2Kb MoAb specific for donor (20-8-45 , a gift from D. Sachs) or anti-H2Kk specific for host-type major histocompatibility complex (MHC) antigens (H-100-5R28, a gift from G. Hammerling), and the second MoAb was FITC-conjugated goat anti-mouse IgG2A (Nordic Immunological Laboratories, Tilburg, The Netherlands). The relative staining of the chimeric cells with each antibody was recorded in a fluorescence-activated cell sorter (FACS). Forward light scatter was used to gate out erythrocytes and dead cells, and the threshold for positive staining among the total leukocyte population was such that the number of cells stained with the second MoAb alone did not exceed 10%. Donor-type chimeras were recorded when
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more than 30% of the cells were positive with anti-H2Kb antibody, and mixed chimeras were recorded when the number of positive cells with anti-H2Kb and anti-H2Kk exceeded 30% for each antibody. The 30% cutoff was established based on preliminary experiments in which the anti-H2Kk and anti-H2Kb antibodies were tested on spleen cells from normal C3H/HeJ and C57BL/6 mice. Such a high cutoff was necessary to avoid false positives.
RESULTS
Effect of different radiation protocols on durable engraftment of T-cell-depleted BM allografts. The following radiation protocols were compared for their ability to enhance donor-type chimerism in mice receiving allogeneic T-cell-depleted BM: (a) a single dose of 8.5 Gy TBI delivered at a dose rate of 0.2 Gy/min; (b) fractionated 12 Gy TBI administered in six fractions (2 Gy, twice a day in 3 days) at a dose rate of 0.1 Gy/min; (c) hyperfractionated 14.4 Gy TBI administered in 12 fractions (1.2 Gy, three times a day in 4 days) at a dose rate of 0.1 Gy/min; and (d) a single dose of 8 Gy TBI at a dose rate of 0.63 Gy/min, routinely used in our mouse model." BMT was performed within 24 hours of completion of irradiation.
As shown in Table 1 , optimal engraftment of donor-type cells was achieved by conditioning the recipients with the single-dose 8.5 Gy TBI protocol (group l), whereas the poorest engraftment was found in mice conditioned with 14. 4 Gy hyperfractionated radiation (group 3).
In two independent experiments, transplantation of 4 x lo6 T-cell-depleted BM cells in group 1 resulted in excellent survival (1 5 of 15 and 19 of 20) and in a high incidence of donor-type chimeras (87% and 89%, respectively). In group 3, on the other hand, survival was poor (6 of 15 and 8 of 15), and surviving mice did not engraft (the percentage of donor-type chimeras was 12.5 and 0, respectively). This difference in survival and donor-type chimerism was highly significant (P < .01 by Fisher's exact test).
Increasing the BM inoculum dose to 8 x lo6 or 12 x lo6 cells enhanced donor-type chimerism in group 3 to 55.5% and loo%, respectively, suggesting that the difference between the two conditioning protocols can be translated into an increase in cell dosage which is greater than an increment of 4 x IO6 cells and less than or equal to an increment of 8 x lo6 cells. Thus, the enhancing effect obtained by using a single dose of 8.5 Gy TBI is equivalent to the effect achieved by doubling or tripling the BM inoculum.
The fractionated radiation protocol (group 2) was similar in its effect to the protocol involving a single dose of 8.0 Gy TBI routinely used in our mouse model (group 4) (P = .83). The percentage of donor-type chimerism after transplantation of 4 x IO6 cells was 33.3% in group 2 and 37.5% in group 4. This apparent advantage over group 3 was not significant, however (P > .05 by Fisher's exact test).
In preliminary experiments (data not shown), when 2 to 10 x lo6 T-celi-depleted BM cells from C57BL/6 donors were transplanted into 8 Gy TBI-treated C3H/HeJ recipients, the rate of hematopoietic reconstitution 2 weeks posttransplant correlates to the BM cell dose. In later periods (3 to 4 weeks) posttransplant, the differences in hematologic parameters Engraftment rate after diferent radiation protocols.
For between mice receiving varying amounts of BM cells do not correlate with BM cell dose and the differences will gradually disappear. Therefore, hematopoietic reconstitution was tested on day 12 posttransplant in mice receiving different radiation regimens.
As shown in Table 2 , engraftment rate was correlated to the percentage of donor-type chimerism, as well as with long-term survival data. After a transplant of 4 x IO6 BM cells, most hematologic parameters in group 1 were markedly superior to those of the other groups, whereas the poorest engraftment rate was observed among recipients of the hyperfractionated protocol (group 3). The average leukocyte number, hemoglobin level, and platelet count in group 1 were 2.2 x 103/pL, 13 g/dL, and 437 x 103/pL, respectively, as compared with 1.0 x 103/pL, 6.7 g/dL, and 127 x 103/pL, respectively, in group 3 (Table 2, experiment 2). This difference was highly significant (P < .01 by Student's t test) for the hemoglobin values and the platelet numbers. The hematologic status in group 1 after transplantation of 1 x lo6 BM cells was slightly superior to that of group 3 after transplantation of 4 x lo6 BM cells. The average leukocyte number and platelet count were comparable. Hemoglobin levels were higher in group 1 (8.4 v 6.7 g/dL, P < .05 by Student's t test). When the BM dose was increased from 4 x lo6 to 12 x IO6 cells, the engraftment rate in mice receiving hyperfractionated radiation (group 3) was slightly lower than that found after 3 x lo6 BM cells were transplanted into mice receiving a single dose of 8.5 Gy TBI (group 1). The differences in leukocyte and platelet numbers were not significant, whereas hemoglobin levels were significantly higher in group 1 (P < .01). Thus, the difference between the two radiation protocols, as reflected by engraftment rate, is equivalent to at least a fourfold increment in the BMT inoculum.
Effect of radiation dose rate on engraftment of T-celldepleted BM allografts. It was shown previously that changes in the rate at which radiation is administered may affect BM engraftment.2' Thus, we wished to quantify the effect of radiation dose rate on BM engraftment in the particular mouse model described above and to compare the results to the effect achieved by substituting one radiation protocol for another.
As shown in Tables 3 and 4 , a marked effect was found when a fixed total dose of 8 Gy TBI was administered but the radiation dose rate was changed. On a change in dose rate from 0.1 to 1.3 Gy/min in recipients of 4 x lo6 T-celldepleted BM cells, donor-type chimerism was enhanced from 0% to 88.6%. Increasing the BM cell dose to 8 x lo6 T-cellkdepleted BM cells after conditioning with 0.1 Gy/min only slightly enhanced the percentage of donor-type chimerism, from 0% to 13.3%, whereas a small BM inoculum of 2 x lo6 T-cell-depleted BM cells afforded 66.6% donor-type chimerism in mice conditioned with 1.3 Gy/min. Thus, the effect on BM engraftment observed when the radiation dose rate was increased from 0.1 to 1.3 Gy/min is more pronounced than the effect obtained by a fourfold increase in BM cell dose.
A similar pattern was also reflected in the hematologic parameters of mice tested 12 days posttransplant; eg, the average hemoglobin level noted in mice irradiated at a dose rate of 1.3 Gy/min and transplanted with 2 x IO6 cells was 10.2 g/dL, as compared with 6.5 g/dL in mice irradiated at a dose rate of 0.1 Gy/min and transplanted with 8 x lo6 T-cell-depleted BM cells. Despite enhanced engraftment of donor cells in the group treated with a dose rate of 1.3 Gy/min, the survival of these mice was lower (owing to infection with gram-negative pathogens) than that of mice in the other groups. Thus, among mice treated with dose rates less than 0.7 Gy/min, 0.7 to 0.8 Gy/min, or 1.3 Gy/min, survival was 47 of 60 (78.3%), 44 of 62 (70.9%), and 39 of 64 (60.9%), respectively. These differences were highly significant (P < .001 by Fisher's exact test).
DISCUSSION
In recent years, many researchers have investigated the relationship between radiation dose rate and the fractional survival of colony-forming units (CFU), 8 to 10 days posttransplant. In these studies, most of which were reviewed in 1983 by Glasgow et a122 and more recently confirmed and extended by Evans et and Tarbell et no significant effect on CFU could be demonstrated, although a marked effect was shown on survival 30 days postirradiation. The short-term CFU assay may not be sensitive enough, however, to detect the low incidence of residual host-type stem cells remaining after the heavy TBI used in the conditioning of leukemia patients.
Using the same murine model as that used in the present study, we previously showed that transplantation of a small dose of 1 x lo6 T-cell-depleted BM cells enhanced survival to 82% as compared with a survival rate of 29% in irradiated mice that did not receive a transplant. This enhancement was associated with a transient engraftment of donor-type cells during the initial posttransplant period. In these transient chimeras, host-type cells remaining after conditioning gradually replaced the initial donor-type graft.12 Similar "reversals" were reported in other murine models using different mouse strains:5 or different conditioning protocols.25 Thus, the presence of a marked signal of host type cells, 30 to 60 days For personal use only. on November 10, 2017. by guest www.bloodjournal.org From posttransplant, has been shown to serve as a sensitive indicator for the effect of different radiation regimens or drugs on the expression of host pluripotent stem cells.
Our results contradict those based on the short-term CFU assay, in that they clearly show a pronounced effect of radiation dose rate on the late expression of host-type cells (progeny of residual host-type pluripotent stem cells). Indeed, this effect was found to be similar in its magnitude to that achieved by adding a myeloablative drug such as busulphan or DMM to the conditioning protocol involving 8 Gy TBI delivered at a dose rate of 0.67 Gy/min.I3
These conflicting results can be resolved if we assume that changes in radiation dose rate may selectively affect the very early stem cells, which play a critical role in BM engraftment and in establishment of durable donor-type chimerism but do not affect the short-term CFU. A similar selective effect on CFU that possess a greater self-renewal capacity has been attributed in several studies to b u s~l p h a n .~~~~'
The late appearance of host-type blood cells may be a reflection not only of host stem cell survival, however, but also of host-type lymphocytes, which may reject donor cells and indirectly alter the balance in favor of host-type cells.
In a recent study, we demonstrated the relative advantage of myeloablative drugs over the lymphotoxic drug cyclophosphamide in our murine model. We showed that although administration of 120 mg/kg cyclophosphamide abrogated clonable T cells more effectively than DMM, thiotepa, or b~s u l f a n , '~ it did not enhance donor-type chimerism when added to 8 Gy TBI. Considering the marked enhancement of BM allografts achieved by addition of myeloablative drugs to 8 Gy TBI, we tend to favor the possibility that direct elimination of stem cells is critical for donor-type engraftment in this particular setting. Further studies using transplantation between congenic strains of mice may be needed to resolve this issue, however.
The sensitivity of our mouse model in detecting the expression of residual host stem cells also permitted us to investigate different radiation protocols currently used in the conditioning of leukemia patients before BMT. Two conclusions can be drawn from our results:
First, the single dose 8.5 Gy TBI protocol similar to that used by Kersey et is by far the most effective in attaining donor-type chimerism after transplantation of T-cell-depleted BM. This simple procedure may be particularly suitable for conditioning of human leukocyte antigen (HLA)-mismatched recipients, in whom engraftment after conditioning with fractionated or hyperfractionated radiation is extremely problematic.
Second, until the toxicity of the single-dose protocol is evaluated, fractionation of radiation is desired. Our results suggest that of the two protocols that involve fractionation of radiation, fractionated radiation (six times 2 Gy, group 2) may be slightly superior to hyperfractionated radiation (group 3) in its effect on donor-type chimerism or on host-type stem cell "relapse." This minor advantage was of low statistical significance, however, and may be negligible (P > .05 by Fisher's exact test).
Clearly, in leukemia patients, usefulness of the single-dose TBI regimen depends not only on its toxicity or its myeloid and lymphoid ablative potential, but also on its ability to abrogate pathologic cells. A major prospective randomized clinical study, comparing a single-dose 10 Gy TBI protocol to a fractionated 12 Gy TBI protocol, showed that in both groups the leukemia relapse rate was identical, suggesting that the two regimens were roughly equivalent in terms of leukemic cell Survival was better in patients receiving the fractionated protocol, owing entirely to a decreased rate in deaths caused by complications.28 If leukemic cells from acute leukemias or chronic myelogenous leukemia have cell survival characteristics similar to those of normal BM stem cells, our present study suggests that the leukemic cells may be abrogated more efficiently by the single-dose 8.5 Gy TBI protocol.
Shank et a129 suggested that hyperfractionated radiation may ablate normal bone BM cells as well as leukemic cells more effectively because it was believed that cell cycle effects may exist that alter radiosensitivity in succeeding fractions. Our results do not support this hypothesis, in that "relapse" of normal host-type blood cells is significantly higher in mice conditioned with hyperfractionated TBI. Conflicting results reported in the literature appear to show greater variation in the response of leukemic cells to radiation as compared with normal cells, h o w e~e r .~~'~~ The radiation protocols we tested are generally supplemented in the clinic with exactly the same chemotherapy ( 2 x 60 mg/kg cyclophosphamide). Therefore, variabilities in the outcome of different conditioning protocols probably should be linked to the radiation component of the protocol.
Thus, in our experiments we studied the effect of the radiation component to elucidate its ablative role in the absence of chemotherapy. The outcome of the combined protocol (TBI plus cyclophosphamide) may not be predicated on the effect of TBI alone, however, as some synergism between these modalities may occur. Further studies in our mouse model using both TBI and cyclophosphamide are required to establish the relevance of the present results to clinical BMT.
Finally, several studies in different animal models indicate that, in principle, single-dose TBI will afford more efficient engraftment of BM allografts than fractionated radiation.Z3. [34] [35] [36] The novelty of the present study lies in its direct comparison of detailed conditioning protocols currently used in different clinical centers, using a well-calibrated mouse model for transplantation of T-cell-depleted BM. In this model, the relative advantage of a given protocol can be translated into an equivalent increase in BM inoculum. Thus, we are able to quantify engraftment efficiency, as well as the repression of host-type stem cells, the progeny of which can emerge only if mice are kept alive long enough after BMT.
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